GSA Capital Partners LLP Has $2.21 Million Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

GSA Capital Partners LLP reduced its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO – Free Report) by 12.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 773,547 shares of the company’s stock after selling 111,174 shares during the quarter. GSA Capital Partners LLP owned about 0.58% of Organogenesis worth $2,212,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ORGO. Pallas Capital Advisors LLC acquired a new position in shares of Organogenesis during the second quarter worth approximately $38,000. Delap Wealth Advisory LLC bought a new stake in Organogenesis during the 2nd quarter valued at $40,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after buying an additional 15,369 shares in the last quarter. Mackenzie Financial Corp lifted its stake in shares of Organogenesis by 46.1% in the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after buying an additional 7,678 shares in the last quarter. Finally, CWM LLC grew its holdings in shares of Organogenesis by 301.8% during the second quarter. CWM LLC now owns 25,617 shares of the company’s stock valued at $72,000 after buying an additional 19,242 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Trading Up 6.7 %

ORGO opened at $3.50 on Tuesday. Organogenesis Holdings Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $4.70. The firm has a market capitalization of $464.00 million, a PE ratio of -26.46 and a beta of 1.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.73 and a quick ratio of 2.42. The company’s 50-day moving average is $2.90 and its 200 day moving average is $2.78.

Organogenesis Company Profile

(Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.

Featured Stories

• Five stocks we like better than Organogenesis
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Oil’s Ready to Rally: 3 Stocks to Buy as the Energy Sector Heats
• What is Put Option Volume?
• Yum! Brands vs. McDonald’s: Which Stock Is the Better Buy?
• What is a Special Dividend?
• The S&P 500 Can Gain 20% and Hit 7,400: Here’s How

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGO – Free Report).